REMSleep Patent Application Has Been Allowed by the United States Patent and Trademark Office
REMSleep Holdings, Inc. (OTCQB: RMSL) has received approval for another utility patent for its Nasal Ventilation System from the United States Patent and Trademark Office. The company expects to be awarded the patent in about 8 weeks after filing the necessary paperwork. REMSleep is awaiting silicone raw materials, expected to arrive in early October, to begin production of the Deltawave CPAP pillows interface.
Following the Deltawave launch, REMSleep plans to submit a 510K application for its next-generation product, 'Longevity', with an expected clearance time of approximately 5 months. The company also anticipates launching a third-generation CPAP interface mask by the end of 2025. REMSleep projects significant growth, expecting to become a substantial company by the end of 2025.
REMSleep Holdings, Inc. (OTCQB: RMSL) ha ricevuto l'approvazione per un altro brevetto utility per il suo Sistema di Ventilazione Nasale dall'Ufficio Statunitense dei Brevetti e dei Marchi. L'azienda si aspetta di ricevere il brevetto tra circa 8 settimane dopo aver presentato la documentazione necessaria. REMSleep sta aspettando i materiali grezzi in silicone, previsti per arrivare all'inizio di ottobre, per iniziare la produzione dell'interfaccia per cuscini Deltawave CPAP.
Dopo il lancio del Deltawave, REMSleep prevede di presentare una domanda 510K per il suo prodotto di nuova generazione, 'Longevity', con un tempo di attesa per l'approvazione di circa 5 mesi. L'azienda prevede anche di lanciare una maschera interfaccia CPAP di terza generazione entro la fine del 2025. REMSleep prevede una crescita significativa, aspettandosi di diventare un'azienda sostanziale entro la fine del 2025.
REMSleep Holdings, Inc. (OTCQB: RMSL) ha recibido la aprobación para otra patente de utilidad para su Sistema de Ventilación Nasal por parte de la Oficina de Patentes y Marcas de Estados Unidos. La empresa espera recibir la patente en aproximadamente 8 semanas después de presentar la documentación necesaria. REMSleep está a la espera de materias primas de silicona, que se espera lleguen a principios de octubre, para comenzar la producción de la interfaz de almohadas CPAP Deltawave.
Tras el lanzamiento del Deltawave, REMSleep planea presentar una solicitud 510K para su producto de nueva generación, 'Longevity', con un tiempo de aprobación esperado de aproximadamente 5 meses. La empresa también anticipa lanzar una máscara de interfaz CPAP de tercera generación para finales de 2025. REMSleep proyecta un crecimiento significativo, esperando convertirse en una empresa sustancial para finales de 2025.
REMSleep Holdings, Inc. (OTCQB: RMSL)는 미국 특허청으로부터 코 통기 시스템에 대한 또 다른 유틸리티 특허 승인을 받았습니다. 회사는 필요한 서류를 제출한 후 약 8주 이내에 특허를 받을 것으로 예상하고 있습니다. REMSleep은 Deltawave CPAP 베개 인터페이스의 생산을 시작하기 위해 10월 초에 도착할 것으로 예상되는 실리콘 원자재를 기다리고 있습니다.
Deltawave 출시 후, REMSleep은 차세대 제품인 'Longevity'에 대한 510K 신청서를 제출할 계획이며, 예상 승인 기간은 약 5개월입니다. 이 회사는 2025년 말까지 3세대 CPAP 인터페이스 마스크를 출시할 예정입니다. REMSleep은 2025년 말까지 상당한 기업으로 성장할 것으로 예상합니다.
REMSleep Holdings, Inc. (OTCQB: RMSL) a reçu l'approbation d'un autre brevet d'utilité pour son Système de Ventilation Nasale par l'U.S. Patent and Trademark Office. L'entreprise s'attend à recevoir le brevet dans environ 8 semaines après avoir déposé les documents nécessaires. REMSleep attend des matières premières en silicone, qui devraient arriver début octobre, pour commencer la production de l'interface de coussins CPAP Deltawave.
Suite au lancement de Deltawave, REMSleep prévoit de soumettre une demande 510K pour son produit de nouvelle génération, 'Longevity', avec un délai d'approbation d'environ 5 mois. L'entreprise prévoit également de lancer un masque interface CPAP de troisième génération d'ici la fin de 2025. REMSleep projette une croissance significative, s'attendant à devenir une entreprise substantielle d'ici la fin de 2025.
REMSleep Holdings, Inc. (OTCQB: RMSL) hat die Genehmigung für ein weiteres Gebrauchsmuster für sein Nasenbelüftungssystem vom US-Patent- und Markenamt erhalten. Das Unternehmen erwartet, das Patent in etwa 8 Wochen nach Einreichung der erforderlichen Unterlagen zu erhalten. REMSleep wartet auf Silikonrohstoffe, die Anfang Oktober eintreffen sollen, um mit der Produktion des Deltawave CPAP-Kisseninterfaces zu beginnen.
Nach dem Start von Deltawave plant REMSleep, einen 510K-Antrag für sein Produkt der nächsten Generation, 'Longevity', zu stellen, dessen Genehmigungszeit voraussichtlich etwa 5 Monate beträgt. Das Unternehmen rechnet außerdem damit, bis Ende 2025 eine CPAP-Interface-Maske der dritten Generation auf den Markt zu bringen. REMSleep prognostiziert signifikantes Wachstum und erwartet, bis Ende 2025 ein erhebliches Unternehmen zu werden.
- Approval of another utility patent for Nasal Ventilation System
- Imminent production and launch of Deltawave CPAP pillows interface
- Planned 510K application for next-generation 'Longevity' product
- Development of third-generation CPAP interface mask by end of 2025
- Projected substantial company growth by end of 2025
- Potential delays in production due to supply chain issues for silicone raw materials
- 5-month waiting period for 510K clearance of 'Longevity' product
CLEARWATER, FL, Sept. 03, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL) announces that another utility patent for its Nasal Ventilation System has been allowed by the United States Patent and Trademark Office. REMSleep will file the necessary paperwork to pay for issuance and, thereafter, REMSleep should be awarded a patent in approximately 8 weeks. REMSleep will maintain a continuation application for adding any improvements and/or changes to the patent lineage.
REMSleep is now waiting on delivery of silicone raw materials from supply chain to produce inventory for market launch. We are expecting materials to arrive to manufacturer approximately first week of October. Production should be available a few days after and we will begin shipping samples to distributors, etc. During this period, we are making all necessary preparations to be fully regulatory compliant with FDA for the launch of the Deltawave CPAP pillows interface.
Immediately after launch of the Deltawave REMSleep intends to submit 510K application for its next generation “Longevity”. The Longevity CPAP pillows interface 510K application is expected to take approximately 5 months to clearance. The “Longevity” design is complete, and no additional R&D is needed. There will be a third generation CPAP interface mask to follow Longevity. We expect to have the third-generation pillows mask to market by end of 2025. We expect REMSleep to be a substantial company by end of 2025.
About REMSleep Holdings, Inc.
REMSleep Holdings, Inc. is a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients. Our focus is primarily designing and manufacturing devices and products for the treatment of sleep apnea and other respiratory conditions. With over 30 years of collective experience in CPAP therapy, the REMSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance. We diligently strive for our products to make a difference and improve the condition of those suffering from sleep apnea.
Forward-looking Statements
This press release may contain forward-looking statements regarding the Company. All statements, other than statements of historical fact included herein, are "forward-looking statements" including statements regarding the Company’s future prospects and risks in investing in Company’s common stock. These statements are based upon the Company's current expectations and speak only as of the date hereof. Financial performance in one period does not necessarily mean continued or better performance in the future. The Company's actual results in any endeavor may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, which factors or uncertainties may be beyond our ability to foresee or control. Other risk factors include the status of the Company's common stock as a "penny stock" and those risk factors stated in reports filed with the U.S. Securities and Exchange Commission or SEC on its EDGAR website (URL:www.sec.gov)
Contact:
REMSleep Holdings, Inc.
14175 ICOT Blvd
Suite 300
Clearwater, FL 33760
Email: twood@remsleep.com
Phone: 912-590-2001
FAQ
When will REMSleep (RMSL) receive its new patent for the Nasal Ventilation System?
What is the timeline for the production of REMSleep's (RMSL) Deltawave CPAP pillows interface?
What is REMSleep's (RMSL) plan for the 'Longevity' CPAP pillows interface?
When does REMSleep (RMSL) expect to launch its third-generation CPAP interface mask?
